<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01670474</url>
  </required_header>
  <id_info>
    <org_study_id>PROCOPrt-PA</org_study_id>
    <secondary_id>Cath-a-lysis</secondary_id>
    <nct_id>NCT01670474</nct_id>
  </id_info>
  <brief_title>Prolonged Hemodialysis Catheter Survival With Copolymer Coating and Rt-PA</brief_title>
  <acronym>PROCOPrt-PA</acronym>
  <official_title>Prolonged Hemodialysis Catheter Survival With Copolymer Coating and Rt-PA - PROCOPrt-PA Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier du Centre du Valais</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier du Centre du Valais</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Surface thrombogenicity of standard double lumen catheters (stDLC) and surface modified&#xD;
      film-coated domain structured double lumen catheters (fcDLC) consisting of a novel reactive&#xD;
      polyurethane copolymer coating showed that in vitro measured surface thrombogenicity was&#xD;
      reduced in the modified catheter compared with standard catheter. The clinical investigation&#xD;
      revealed that both number of days before catheter removal according to clinical requirements&#xD;
      and number of treatments per catheter were significantly higher with the modified catheter as&#xD;
      compared with the standard catheter.&#xD;
&#xD;
      Recombinant tissue plasminogen activator (rt-PA) has been used primarily to treat catheter&#xD;
      thrombosis. The relatively high cost of rt-PA and its theoretical potential to cause&#xD;
      bleeding, as well as the morbidity and mortality associated with catheter malfunction and&#xD;
      infection, justify the need for more definitive evidence of the efficacy of rt-PA as a&#xD;
      locking solution.&#xD;
&#xD;
      No study aims to evaluate the impact of rt-PA locking in long-term Hemodialysis (HD) uncuffed&#xD;
      catheters survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The solution instilled into the central venous catheter lumens after each HD session and left&#xD;
      in the catheter until the next session (catheter locking solution) is used to prevent&#xD;
      thrombosis during the period between HD sessions and may also prevent catheter-related&#xD;
      infection. However, evidence supporting the use of various locking solutions to achieve these&#xD;
      objectives is limited. Heparin has been the traditional locking solution. Several small&#xD;
      studies have assessed whether citrate and heparin are equally efficacious for maintaining&#xD;
      catheter patency but the interpretation of the results was limited because the studies had a&#xD;
      short follow-up period and included both uncuffed and cuffed central venous catheters.&#xD;
&#xD;
      Thrombosis is a major cause of HD catheter dysfunction, and this problem is rectified by the&#xD;
      use of thrombolytic agents, invasive procedures for declotting, or catheter replacement. A&#xD;
      thrombus at the tip of the catheter or a fibrin sheath around it may resist local&#xD;
      thrombolysis if it is not reached by sufficient concentrations of the drug. Urokinase has&#xD;
      traditionally been used as the thrombolytic agent for HD vascular access declotting, and&#xD;
      success rates for declotting vary from 55% to 85%. However, successful treatment of occluded&#xD;
      central venous catheter (non HD) with recombinant tissue plasminogen activator (rt-PA) or&#xD;
      alteplase was recently achieved in more than 1,000 patients with success (function restored&#xD;
      in 798 patients [75.0%; 95% CI: 72.3 to 77.6%]). Serious adverse events monitored within 30&#xD;
      days was very rare and efficacy was independent of age, sex, body weight, and catheter type.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lifespan patency with the ability to complete HD session in three different UCs using rt-PA locking protocol</measure>
    <time_frame>240 days after patients' enrollement</time_frame>
    <description>The ability to achieve blood flow rates of &gt;= 250 mL/min in three different UCs using rt-PA locking protocol if the UCs present a clotting event (complete or partial thrombosis).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of catheter-related bacteremia after rt-PA use in case of thrombosed UCs</measure>
    <time_frame>240 days after patients' enrollement</time_frame>
    <description>The solution instilled into the central venous catheter lumens after each HD session and left in the catheter until the next session (catheter locking solution) is used to prevent thrombosis during the period between HD sessions and may also prevent catheter-related infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic evaluation of rt-PA in catheter patency after UCs dysfunction</measure>
    <time_frame>240 days after patients' enrollement</time_frame>
    <description>An economic evaluation of rt-PA in catheter patency after dysfunction (partial or complete catheter thrombosis) will be conducted.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of patients who complete HD session with short term HD catheters using rt-PA.</measure>
    <time_frame>240 days after patients' enrollement</time_frame>
    <description>This analysis aims to see if rt-PA will decrease the incidence of catheter malfunction due to thrombosis in three different UCs of different synthetic material.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Malfunction; Catheter</condition>
  <condition>Thrombosis</condition>
  <condition>Mechanical Complication of Hemodialysis Catheter</condition>
  <arm_group>
    <arm_group_label>fmDLC and rt-PA (2mg/2mL actilysis)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Surface thrombogenicity of film-coated domain structured double lumen catheters (fmDLC) consisting of a novel reactive polyurethane copolymer coating will be assessed by measurement of thrombin-antithrombin (TAT) III complex in vitro after the use of rt-PA (2mg/2mL) in each lumen of the catheter for 45 minutes.&#xD;
Each lumen of the thrombosed (dysfunctional) catheter will be locked with the exact volume (luminal volume) of rt-PA (rt-PA (2mg/2mL) actilysis) during 45 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>polyDLC and rt-PA (2mg/2mL actilysis)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The same procedure will be assessed in the polyurethane double lumen catheter (polyDLC)as with the fmDLC. Indeed, surface thrombogenicity of polyDLC will be assessed by measurement of thrombin-antithrombin (TAT) III complex in vitro after the use of rt-PA (2mg/2mL) in each lumen of the catheter for 45 minutes.&#xD;
Each lumen of the thrombosed (dysfunctional) catheter will be locked with the exact volume (luminal volume) of rt-PA (rt-PA (2mg/2mL) actilysis) during 45 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>siDLC and rt-PA (2mg/2mL actilysis)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Same procedure as the previous catheters. Surface thrombogenicity of silicone double lumen catheter (siDLC) will be assessed by measurement of thrombin-antithrombin (TAT) III complex in vitro after the use of rt-PA (2mg/2mL) in each lumen of the catheter for 45 minutes.&#xD;
Each lumen of the thrombosed (dysfunctional) catheter will be locked with the exact volume (luminal volume) of rt-PA (rt-PA (2mg/2mL) actilysis) during 45 min.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rt-PA (2mg/2mL) actilysis</intervention_name>
    <description>At the first catheter dysfunction (Qb &lt; 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. All catheters analyzed (fmDLC, polyDLC and siDLC) will be locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions: i.e. fmDLC, polyDLC amd siDLC.</description>
    <arm_group_label>fmDLC and rt-PA (2mg/2mL actilysis)</arm_group_label>
    <arm_group_label>polyDLC and rt-PA (2mg/2mL actilysis)</arm_group_label>
    <arm_group_label>siDLC and rt-PA (2mg/2mL actilysis)</arm_group_label>
    <other_name>Cathflo, 2mg/2mL (Boehringer Ingelheim, Ingelheim/Germany</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rt-PA</intervention_name>
    <description>At the first catheter dysfunction (Qb &lt; 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed in this study (i.e. fmDLC, polyDLC, siDLC) will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions.</description>
    <arm_group_label>fmDLC and rt-PA (2mg/2mL actilysis)</arm_group_label>
    <arm_group_label>polyDLC and rt-PA (2mg/2mL actilysis)</arm_group_label>
    <arm_group_label>siDLC and rt-PA (2mg/2mL actilysis)</arm_group_label>
    <other_name>Cathflo, 2mg/2mL (Boehringer Ingelheim, Ingelheim/Germany)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  End-stage kidney disease patients with newly inserted temporary untunnelled dual-lumen&#xD;
             catheter&#xD;
&#xD;
          -  Naive to study but not naive to catheters (both virgin and non-virgin catheters will&#xD;
             be included)&#xD;
&#xD;
          -  Expected to use catheter, and to dialyze at study centre, for at least six months&#xD;
&#xD;
          -  Frequency of HD 3 times per week&#xD;
&#xD;
          -  If indication for catheter was replacement for catheter related infection patients&#xD;
             will be eligible after the infection has been treated and the patient has been off&#xD;
             antibiotics for 3 HD sessions&#xD;
&#xD;
          -  Patient or legal representative able to provide written consent&#xD;
&#xD;
          -  Eighteen years of age or older&#xD;
&#xD;
          -  Baseline INR ≤ 1.3 (no anticoagulation allowed outside the HD session)&#xD;
&#xD;
          -  Baseline platelet count ≥ 60 x 109/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of systemic anticoagulation (if indication for anticoagulation is catheter patency&#xD;
             patients may be eligible if the systemic anticoagulation is discontinued and baseline&#xD;
             INR is ≤ 1.3)&#xD;
&#xD;
          -  Insertion of a new catheter into the femoral vein&#xD;
&#xD;
          -  Current use of antibiotics for catheter-related bacteraemia (see inclusion criteria&#xD;
             above)&#xD;
&#xD;
          -  Major haemorrhage in the prior 4 weeks, defined as bleeding resulting in a drop in&#xD;
             haemoglobin of greater than 20 g/L or bleeding requiring transfusion of packed red&#xD;
             blood cells with other clinical evidence or suspicion of bleeding&#xD;
&#xD;
          -  History of intra-cranial bleed in the prior 4 weeks&#xD;
&#xD;
          -  Intra-cranial or intra-spinal neoplasm (current)&#xD;
&#xD;
          -  Allergy or intolerance to rt-PA or heparin or its constituents&#xD;
&#xD;
          -  Active pericarditis - defined by the presence of a pericardial rub&#xD;
&#xD;
          -  Weight ≤ 30 kg or &gt; 130 kg&#xD;
&#xD;
          -  Patient pregnant or lactating&#xD;
&#xD;
          -  Child bearing potential (i.e. pre-menopausal woman who is not using a reliable method&#xD;
             of contraception)&#xD;
&#xD;
          -  Major surgery in past 48 hours (CABG, organ biopsy, puncture of non-compressible&#xD;
             vessels), or scheduled for major surgery during the study period&#xD;
&#xD;
          -  Involvement in another randomized drug trial&#xD;
&#xD;
          -  Presence of a fever as defined by a temperature &gt; 38.2°C&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal Meier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHCVs - RSV - Hôpital du Valais</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pascal Meier, MD</last_name>
    <phone>+41276038647</phone>
    <email>pascal.meier@hopitalvs.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier du Centre du Valais (CHCVs)</name>
      <address>
        <city>Sion</city>
        <state>Valais</state>
        <zip>1950</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Meier, MD</last_name>
      <phone>+41276038647</phone>
      <email>pascal.meier@hopitalvs.ch</email>
    </contact>
    <investigator>
      <last_name>Rachel Meier, SN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Meier P, Meier R, Turini P, Friolet R, Blanc E. Prolonged catheter survival in patients with acute kidney injury on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification. Nephrol Dial Transplant. 2011 Feb;26(2):628-35. doi: 10.1093/ndt/gfq449. Epub 2010 Jul 28.</citation>
    <PMID>20667989</PMID>
  </results_reference>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>March 20, 2012</study_first_submitted>
  <study_first_submitted_qc>August 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2012</study_first_posted>
  <last_update_submitted>August 20, 2012</last_update_submitted>
  <last_update_submitted_qc>August 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier du Centre du Valais</investigator_affiliation>
    <investigator_full_name>Pascal Meier MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Temporary hemodialysis catheters</keyword>
  <keyword>Non-cuffed hemodialysis catheters</keyword>
  <keyword>Thrombolysis</keyword>
  <keyword>rt-PA</keyword>
  <keyword>Thrombosis</keyword>
  <keyword>Lifespan</keyword>
  <keyword>Blood flow rate</keyword>
  <keyword>Catheter related bacteriemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01670474
org study id: PROCOPrt-PA
secondary id: Cath-a-lysis
nct id: NCT01670474
lead sponsor: 
has dmc: Yes
Surface thrombogenicity of standard double lumen catheters (stDLC) and surface modified
      film-coated domain structured double lumen catheters (fcDLC) consisting of a novel reactive
      polyurethane copolymer coating showed that in vitro measured surface thrombogenicity was
      reduced in the modified catheter compared with standard catheter. The clinical investigation
      revealed that both number of days before catheter removal according to clinical requirements
      and number of treatments per catheter were significantly higher with the modified catheter as
      compared with the standard catheter.

      Recombinant tissue plasminogen activator (rt-PA) has been used primarily to treat catheter
      thrombosis. The relatively high cost of rt-PA and its theoretical potential to cause
      bleeding, as well as the morbidity and mortality associated with catheter malfunction and
      infection, justify the need for more definitive evidence of the efficacy of rt-PA as a
      locking solution.

      No study aims to evaluate the impact of rt-PA locking in long-term Hemodialysis (HD) uncuffed
      catheters survival.
The solution instilled into the central venous catheter lumens after each HD session and left
      in the catheter until the next session (catheter locking solution) is used to prevent
      thrombosis during the period between HD sessions and may also prevent catheter-related
      infection. However, evidence supporting the use of various locking solutions to achieve these
      objectives is limited. Heparin has been the traditional locking solution. Several small
      studies have assessed whether citrate and heparin are equally efficacious for maintaining
      catheter patency but the interpretation of the results was limited because the studies had a
      short follow-up period and included both uncuffed and cuffed central venous catheters.

      Thrombosis is a major cause of HD catheter dysfunction, and this problem is rectified by the
      use of thrombolytic agents, invasive procedures for declotting, or catheter replacement. A
      thrombus at the tip of the catheter or a fibrin sheath around it may resist local
      thrombolysis if it is not reached by sufficient concentrations of the drug. Urokinase has
      traditionally been used as the thrombolytic agent for HD vascular access declotting, and
      success rates for declotting vary from 55% to 85%. However, successful treatment of occluded
      central venous catheter (non HD) with recombinant tissue plasminogen activator (rt-PA) or
      alteplase was recently achieved in more than 1,000 patients with success (function restored
      in 798 patients [75.0%; 95% CI: 72.3 to 77.6%]). Serious adverse events monitored within 30
      days was very rare and efficacy was independent of age, sex, body weight, and catheter type.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Single (Participant)
measure: Lifespan patency with the ability to complete HD session in three different UCs using rt-PA locking protocol
time frame: 240 days after patients' enrollement
description: The ability to achieve blood flow rates of >= 250 mL/min in three different UCs using rt-PA locking protocol if the UCs present a clotting event (complete or partial thrombosis).
measure: The incidence of catheter-related bacteremia after rt-PA use in case of thrombosed UCs
time frame: 240 days after patients' enrollement
description: The solution instilled into the central venous catheter lumens after each HD session and left in the catheter until the next session (catheter locking solution) is used to prevent thrombosis during the period between HD sessions and may also prevent catheter-related infection.
measure: Economic evaluation of rt-PA in catheter patency after UCs dysfunction
time frame: 240 days after patients' enrollement
description: An economic evaluation of rt-PA in catheter patency after dysfunction (partial or complete catheter thrombosis) will be conducted.
measure: Number of patients who complete HD session with short term HD catheters using rt-PA.
time frame: 240 days after patients' enrollement
description: This analysis aims to see if rt-PA will decrease the incidence of catheter malfunction due to thrombosis in three different UCs of different synthetic material.
arm group label: fmDLC and rt-PA (2mg/2mL actilysis)
arm group type: Experimental
description: Surface thrombogenicity of film-coated domain structured double lumen catheters (fmDLC) consisting of a novel reactive polyurethane copolymer coating will be assessed by measurement of thrombin-antithrombin (TAT) III complex in vitro after the use of rt-PA (2mg/2mL) in each lumen of the catheter for 45 minutes.
Each lumen of the thrombosed (dysfunctional) catheter will be locked with the exact volume (luminal volume) of rt-PA (rt-PA (2mg/2mL) actilysis) during 45 min.
arm group label: polyDLC and rt-PA (2mg/2mL actilysis)
arm group type: Active Comparator
description: The same procedure will be assessed in the polyurethane double lumen catheter (polyDLC)as with the fmDLC. Indeed, surface thrombogenicity of polyDLC will be assessed by measurement of thrombin-antithrombin (TAT) III complex in vitro after the use of rt-PA (2mg/2mL) in each lumen of the catheter for 45 minutes.
Each lumen of the thrombosed (dysfunctional) catheter will be locked with the exact volume (luminal volume) of rt-PA (rt-PA (2mg/2mL) actilysis) during 45 min.
arm group label: siDLC and rt-PA (2mg/2mL actilysis)
arm group type: Active Comparator
description: Same procedure as the previous catheters. Surface thrombogenicity of silicone double lumen catheter (siDLC) will be assessed by measurement of thrombin-antithrombin (TAT) III complex in vitro after the use of rt-PA (2mg/2mL) in each lumen of the catheter for 45 minutes.
Each lumen of the thrombosed (dysfunctional) catheter will be locked with the exact volume (luminal volume) of rt-PA (rt-PA (2mg/2mL) actilysis) during 45 min.
intervention type: Drug
intervention name: rt-PA (2mg/2mL) actilysis
description: At the first catheter dysfunction (Qb < 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. All catheters analyzed (fmDLC, polyDLC and siDLC) will be locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions: i.e. fmDLC, polyDLC amd siDLC.
arm group label: fmDLC and rt-PA (2mg/2mL actilysis)
arm group label: polyDLC and rt-PA (2mg/2mL actilysis)
arm group label: siDLC and rt-PA (2mg/2mL actilysis)
other name: Cathflo, 2mg/2mL (Boehringer Ingelheim, Ingelheim/Germany
intervention type: Drug
intervention name: rt-PA
description: At the first catheter dysfunction (Qb < 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed in this study (i.e. fmDLC, polyDLC, siDLC) will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions.
arm group label: fmDLC and rt-PA (2mg/2mL actilysis)
arm group label: polyDLC and rt-PA (2mg/2mL actilysis)
arm group label: siDLC and rt-PA (2mg/2mL actilysis)
other name: Cathflo, 2mg/2mL (Boehringer Ingelheim, Ingelheim/Germany)
criteria: 
gender: All
minimum age: 18 Years
maximum age: 79 Years
healthy volunteers: No
last name: Pascal Meier, MD
role: Principal Investigator
affiliation: CHCVs - RSV - Hôpital du Valais
last name: Pascal Meier, MD
phone: +41276038647
email: pascal.meier@hopitalvs.ch
facility: 
status: Recruiting
contact: 
investigator: 
country: Switzerland
citation: Meier P, Meier R, Turini P, Friolet R, Blanc E. Prolonged catheter survival in patients with acute kidney injury on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification. Nephrol Dial Transplant. 2011 Feb;26(2):628-35. doi: 10.1093/ndt/gfq449. Epub 2010 Jul 28.
PMID: 20667989
responsible party type: Principal Investigator
investigator affiliation: Centre Hospitalier du Centre du Valais
investigator full name: Pascal Meier MD
investigator title: Professor
mesh term: Thrombosis
mesh term: Tissue Plasminogen Activator